PharmaShots Weekly Snapshot (December 03

1.Genentechs Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations Published: 6 Dec, 2018 | Tags: Genentech, Tecentriq, Receives, FDA, Approval, Combination Therapy, Treat, mNon-Sq, NSCLC, No EGFR, ALK, Genomic Tumor Aberrations

Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for CRISPR/Cas9-Based Therapy

Published: 6 Dec, 2018 | Tags: Novartis, Reports, Results, BYL719, (alpelisib), fulvestrant, P-III, SOLAR-1, HR+/HER2- Advanced Breast Cancer

Biogen Exercises Exclusive Worldwide Option to Develop & Commercialize Ioniss BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS)

Published: 6 Dec, 2018 | Tags: Biogen, Exercises, Option, Develop, Commercialize, Ionis, BIIB067, (IONIS-SOD1RX), Amyotrophic Lateral Sclerosis (ALS), SOD1 mutations

Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer

Published: 6 Dec, 2018 | Tags: Novartis, Reports, Results, BYL719, (alpelisib), fulvestrant, P-III, SOLAR-1, HR+/HER2- Advanced Breast Cancer

Subtle an AI based Medical Device SubtlePET Receives FDAs 510(K) Clearance

Published: 6 Dec, 2018 | Tags: Subtle, AI, based, Medical Device, SubtlePET, Receives, FDA, 510(K) Clearance

Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders

Published: 5 Dec, 2018 | Tags: Roche, Collaborates, Icagen, Development, Drug, Candidates, Neurological Disorders

Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)

Published: 6 Dec, 2018 | Tags: Roche, Reports, Results, Kadcyla, (trastuzumab emtansine), Herceptin, (trastuzumab) P-III, KATHERINE Study, HER2-positive Early Breast Cancer (eBC) 8.NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US Published: 5 Dec, 2018 | Tags: NeuroPace, Reports, Positive, Results, Next-Gen RNS System, Refractory, Epilepsy, the US

Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

Published: 5 Dec, 2018 | Tags: Innovate, Massachusetts General Hospital, Collaborates, Develop, Alcoholic Liver Diseases, Celiac Disease

Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)

Published: 5 Dec, 2018 | Tags: Domain Therapeutics, Signs, Research, License, Agreement, Boehringer Ingelheim (BI) , G-Protein Coupled Receptors (GPCRs)

Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Published: 5 Dec, 2018 | Tags: Celltrion, Reports, Results, CT-P10, (rituximab, biosimilar), P-III, Advance Follicular Lymphoma, Rituxan

Gileads Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA s (CFDA) Approval for HIV-1 Infection

Published: 5 Dec, 2018 | Tags: Gilead, Descovy, (Emtricitabine, Tenofovir Alafenamide), Receives, NMPA, CFDA, Approval, HIV-1 Infection 13.Crown Laboratories Acquires Rights for GSKs Five OTC Drugs Published: 30 Nov, 2018 | Tags: Crown Laboratories, Acquires, Rights, GSKs, Five, OTC Drugs

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018

Published: 2 Dec, 2018|Tags: Kite, Reports, Results, Yescarta, (axicabtagene ciloleucel), ZUMA-1, Refractory, Large B-Cell, Lymphoma

Cilag Acquires Exclusive Worldwide Rights of Argenxs Cusatuzumab (ARGX-110) for $1.6B

Published: 4 Dec, 2018|Tags: Cilag Acquired Exclusive Worldwide Rights of Argenxs Cusatuzumab (ARGX-110) for $1.6B

AbbVie Signs a Worldwide Non-Exclusive License Agreement for Humiras (adalimumab) Patent Rights with Pfizer

Published: 4 Dec, 2018|Tags: AbbVie, Signs, Worldwide, Non-Exclusive, License, Agreement, Humira, (adalimumab), Patent, Rights, Pfizer

GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (£4.0 billion)

Published: 3 Dec, 2018|Tags: GSK, Acquire, Tesaro, Zejula, (niraparib), $5.1B,(£4.0 billion), Ovarian, Prostate, Lung

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma

Published: 3 Dec, 2018|Tags: Pfizer, Reports, Results, PF-05280586, (rituximab biosimilar), REFLECTIONS B328-06 study, CD20-Positive Non-Hodgkin Lymphoma